

**OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")**

Investor presentation and SweetBiotix® Sampling

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces that further to the announcement on 14 May 2026, the Company has confirmed details of its investor presentation and SweetBiotix® product sampling event.

The Company received a high level of interest following the announcement on 14 May 2026 and has booked a suitable venue in central London for the event.

The evening event will provide investors an overview of the commercial progress of its first-generation products, routes to market for its second generation products, and sampling of SweetBiotix.

The event will also provide shareholders and investors with an opportunity to hear directly from management and ask questions regarding the business and its product pipeline.

The event will be held in Central London a short walk from Holborn underground station on:

Date: Wednesday 24 June 2026

Time: 7:00pm

Spaces are limited, so please register your attendance using the link [OptiBiotix Health PLC Investor Meeting - Luma](#) to secure your place and confirm full venue details. This should take less than 1 minute.

View the full announcement and submit questions to management via our website: <https://optibiotix.com/link/egG23e>

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

About OptiBiotix : www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be

notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFLFFERFILIR